PXD101 IN PATIENTS WITH RECURRENT OR REFRACTORY CUTANEOUS AND PERIPHERAL T-CELL

PXD101 在复发性或难治性皮肤及外周 T 细胞患者中的应用

• 批准号: 7605249
• 负责人: RAJ ADVANI
• 金额: $ 1.52万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-15 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605249
• 关键词: Antineoplastic Agents; Cells; Clinical Treatment; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Cutaneous; Disease; Funding; Grant; In complete remission; Institution; Investigational Drugs; Label; Measures; Multiple Myeloma; Neoplasms; Non-Hodgkin' s Lymphoma; PXD101; Patients; Peripheral; Phase; Phase II Clinical Trials; Prior Therapy; Progressive Disease; Randomized; Rate; Recurrence; Recurrent disease; Refractory; Relapse; Research; Research Personnel; Resources; Safety; Source; Stable Disease; T-Cell Lymphoma; Time; United States National Institutes of Health; Upper arm; design; partial response; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is an open-label, non-randomized, multicenter, Phase II trial to assess the efficacy and safety of an investigational drug, PXD101, monotherapy in patients who have failed at least one line of prior therapy. The trial design includes two arms; arm A comprises only patients with recurrent Cutaneous T-cell lymphoma (CTCL), and arm B comprises patients with relapsed or refractory Peripheral T-cell Lymphoma (PTCL) or other T-cell lymphomas. PXD101 is a promising antineoplastic agent for the treatment of hematological neoplasias, and is currently being evaluated in a Phase II clinical trial for the treatment of multiple myeloma. Further clinical trials in patients with Non-Hodgkin's lymphomas (NHL) will delineate the optimal use of PXD101 in these disorders. The primary objective of this trial is to determine the efficacy of PXD101 treatment as measured by response rate (CR=complete response; CRu=CR/unconfirmed; PR=partial response; SD=stable disease; RD=relapsed disease; or PD=progressive disease) using the response criteria of Cheson et al. (Cheson 1999). The secondary objective of the trial is to examine the time to response, the duration of response, and the safety and survival following PXD101 therapy as a single agent.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这是一项开放标签、非随机、多中心、II期试验，旨在评估研究药物PXD 101单药治疗至少一线既往治疗失败的患者的疗效和安全性。 试验设计包括两组; A组仅包括复发性皮肤T细胞淋巴瘤（CTCL）患者，B组包括复发性或难治性外周T细胞淋巴瘤（PTCL）或其他T细胞淋巴瘤患者。 PXD 101是一种很有前途的治疗血液肿瘤的药物，目前正在进行治疗多发性骨髓瘤的II期临床试验。在非霍奇金淋巴瘤（NHL）患者中进行的进一步临床试验将描述PXD 101在这些疾病中的最佳用途。 本试验的主要目的是使用Cheson et al.（Cheson 1999）的缓解标准，通过缓解率（CR=完全缓解; CRu=CR/未证实; PR=部分缓解; SD=疾病稳定; RD=疾病复发;或PD=疾病进展）测定PXD 101治疗的疗效。该试验的次要目的是检查PXD 101作为单一药物治疗后的反应时间，反应持续时间以及安全性和生存期。